Zymeworks Inc Q & A Q: What’s the story about Zymeworks entering into a deal with Royalty Pharma? A: Zymeworks and Royalty Pharma have already entered into $250 Million Royalty-Backed Note Financing. Zymeworks (
BridgeBio Pharma in the NEWS On March 11, 2026, BridgeBio Pharma (BBIO) presented additional positive data from the interim analysis of FORTIFY, the Phase 3 clinical trial of oral BBP-418, in individuals with limb-girdle muscular dystrophy type . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Vertex Pharmaceuticals in the NEWS March 9, 2026, Vertex Pharmaceuticals (VRTX) today announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). The trial . . . This content is …
Mirum Pharmaceuticals Mirum Pharmaceuticals (MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities. From the Experts Tatyana Kushner, M.D., MSCE, Associate Professor of . . . This content is for …
FDA on the Compounded Semaglutide The FDA warns that compounded semaglutide is not FDA-approved, meaning it has not been reviewed for safety, effectiveness, or quality. Following the resolution of drug shortages for Ozempic/Wegovy, the FDA has limited the legal sale of compounded versions. Risks include overdoses from dosing errors (5-20 times the intended dose), mislabeled products, and unknown ingredients. The U.S. Food and Drug Administration (.gov)+5 …
Intellia Therapeutics March 02, 2026 -- Intellia Therapeutics, Inc. (NTLA), announced that the U.S. FDA has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy. From Intellia Therapeutics Intellia President and Chief Executive Officer John Leonard, M . . . This content is for paid …
Intellia Therapeutics in the NEWS February 26, 2026, Intellia Therapeutics, Inc. (NTLA), reported business updates and financial results for the fourth quarter and year ended December 31, 2025. From Intellia Therapeutics Intellia President and Chief Executive Officer John Leonard, M.D, said, “2025 was a time of accomplishment and resiliency for Intellia . . . This content is for paid subscribers. Please click here to subscribe or here to log …
Novo Nordisk in the NEWS February 24, 2026 – Novo Nordisk (NVO) announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Merck - Human Health Business RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK) - known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its . . . This content …
Johnson & Johnson in the NEWS Yesterday, February 18, 2026, Johnson & Johnson (JNJ) announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and . . . This content …
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., February 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA) - a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement . . . This content is for …
Bio-Techne Corp Q2 Financial Results Yesterday, February 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (TECH) reported its financial results for the second quarter ending December 31, 2025. Second Quarter FY2026 Highlights Second quarter revenue . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Intellia Therapeutics News January 27, 2026, Intellia Therapeutics, Inc. (NTLA), today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv . . . This content is for paid subscribers. Please click here to subscribe …
BioCryst Pharmaceuticals Acquires Astria Pharmaceuticals Today, January 23, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) announced it completed acquisition of Astria Therapeutics, Inc., initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema (HAE) and enhances the company’s long-term growth trajectory. BioCryst adds navenibart BioCryst, a late-stage, long . . . This content is for paid subscribers. Please click here to …
Corcept Therapeutics Yesterday, January 22, 2026, Corcept Therapeutics (CORT) - a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant . . . This content is for paid subscribers. Please …
Bristol-Myers Squibb and Microsoft Collaboration Bristol-Myers Squibb (BMY) - a global leader in oncology, announced an agreement with Microsoft, a market leader in AI-powered radiology and clinical workflow technologies, aiming to accelerate early detection of lung cancer. Through this digital health collaboration, U.S. FDA-cleared radiology AI algorithms will be deployed via Microsoft’s Precision Imaging Network . . . This content is for paid subscribers. Please click here …
GSK Agreement to Acquire RAPT Therapeutics Yesterday, January 20, GSK (GSK) announced that it has entered a definitive agreement to acquire RAPT Therapeutics (RAPT) a California-based, clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Sanofi's Myqorzo & Redemplo Paris, January 15, 2026, the National Medical Products Administration in China has approved two Sanofi-licensed innovative medicines, Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), and Redemplo (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) on the basis of dietary control. From Sanofi Olivier Charmeil, Executive Vice President, General Medicines, Sanofi, Said, “We …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
